Trough this study we have seen that CF33 and CF33-Fluc are safe and efective in vitro and in vivo. Trough chimerization and high throughput screening, the novel virus have been created that requires lower doses to treat pancreatic cancer in a preclinical model. CF33-Fluc replication in non-injected, distant tumors halted tumor growth. Further studies in immune-competent models investigating the mechanisms of rapid tumor regression and viral spread to non-injected tumors following a low viral dose will enhance our understanding of how this novel virus targets and kills pancreatic cancer.
Do you want to learn more? Read this interesting article!